Ebola treatment

Search documents
Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks
Globenewswireยท 2025-09-19 11:00
Core Points - Regeneron Pharmaceuticals announced the donation of up to 500 doses of Inmazeb to the WHO for use in low- and lower-middle income countries, ensuring access to this life-saving Ebola treatment [1][2] - Inmazeb is the first FDA-approved treatment for Zaire ebolavirus, developed using Regeneron's VelocImmune platform, consisting of three monoclonal antibodies [3][4] - The safety and efficacy of Inmazeb were established through the PALM Trial, which demonstrated its superiority in preventing death compared to other treatments [5][6] Company Initiatives - Regeneron is actively supplying Inmazeb to the Democratic Republic of the Congo (DRC) amid the current Ebola outbreak, continuing its commitment to provide the treatment at no cost under a compassionate use protocol [2][6] - The company has collaborated with public health agencies and NGOs since 2018 to ensure rapid access to Inmazeb during outbreaks, with 266 patients treated by June 2025 [2][6] Regulatory Milestones - Inmazeb received FDA approval in 2020 and was added to the WHO Essential Medicines List in 2023, becoming the first Ebola treatment to be prequalified by the WHO [6][7] - WHO guidelines published in 2022 strongly recommend Inmazeb for Ebola virus therapeutics, highlighting the need for improved access to such medicines [6] Development Background - Inmazeb was developed with federal funding from the Biomedical Advanced Research and Development Authority (BARDA) and has been part of ongoing U.S. government contracts [7]